Drug intelligence / Profile preview

teslanbaicin

Development stage: Phase 2
Lead developer: The First Affiliated Hospital of Xinxiang Medical College
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Teslanbaicin is an oral live biotherapeutic product consisting of selenium-enriched *Lactobacillus rhamnosus*. Developed by The First Affiliated Hospital of Xinxiang Medical College, it is specifically designed to treat radiation proctitis, a common complication of pelvic radiotherapy. The mechanism of action involves the synergistic effect of the probiotic strain and the trace element selenium. *Lactobacillus rhamnosus* helps restore the balance of the intestinal microbiota, which is often disrupted by radiation, while the incorporated selenium provides potent antioxidant and anti-inflammatory activity. By reducing oxidative stress and modulating the local immune response in the rectal mucosa, Teslanbaicin aims to alleviate the symptoms and tissue damage associated with Grade 1-2 radiation proctitis.

Other names: selenium-enriched Lactobacillus rhamnosusSe-L. rhamnosus

Beyond the preview

Go deeper on teslanbaicin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on teslanbaicin.

Explore the full profile